Neuroscience Bulletin

, Volume 29, Issue 1, pp 111–120 | Cite as

Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer’s disease

  • Lian-Feng Lin
  • Min-Jing Liao
  • Xiao-Yan Xue
  • Wei Zhang
  • Li Yan
  • Liang Cai
  • Xiao-Wen Zhou
  • Xing Zhou
  • Huan-Min LuoEmail author


There is no effective drug to treat Alzheimer’s disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-beta (Aβ) may be a target for developing drugs against AD. Meanwhile, the fact that localized neuronal death/loss and synaptic impairment occur in AD should also be considered. Neuronal regeneration, which does not occur normally in the mammalian central nervous system, can be promoted by neurotrophic factors (NTFs). Evidence from clinical trials has shown that both Aβ clearance and NTFs are potentially effective in treating AD, thus a new approach combining Aβ clearance and administration of NTFs may be an effective therapeutic strategy.


Alzheimer’s disease amyloid-beta neurotrophic factors treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Lin LF, Luo HM. Screening of treatment targets for Alzheimer’s disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation. Neurosci Bull 2011, 27: 53–60.PubMedCrossRefGoogle Scholar
  2. [2]
    Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 2011, 3: 77sr71.Google Scholar
  3. [3]
    Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician 2011, 83: 1403–1412.PubMedGoogle Scholar
  4. [4]
    Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2: a006395.PubMedGoogle Scholar
  5. [5]
    Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, et al. N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res 2012, 9(6): 746–758.PubMedGoogle Scholar
  6. [6]
    Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, et al. Abeta(1–42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 2011, 14(5): 545–547.PubMedCrossRefGoogle Scholar
  7. [7]
    Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008, 14: 837–842.PubMedCrossRefGoogle Scholar
  8. [8]
    Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, et al. Tau protein is required for amyloid ta-induced impairment of hippocampal long-term potentiation. J Neurosci 2011, 31: 1688–1692.Google Scholar
  9. [9]
    Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer’s disease. J Neurosci 2009, 29: 9321–9329.PubMedCrossRefGoogle Scholar
  10. [10]
    Van Muiswinkel FL, Veerhuis R, Eikelenboom P. Amyloid beta protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. J Neurochem 1996, 66: 2468–2476.PubMedCrossRefGoogle Scholar
  11. [11]
    Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 1994, 91: 3270–3274.PubMedCrossRefGoogle Scholar
  12. [12]
    Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293: 1491–1495.PubMedCrossRefGoogle Scholar
  13. [13]
    Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009, 118: 103–113.PubMedCrossRefGoogle Scholar
  14. [14]
    Serlin Y, Levy J, Shalev H. Vascular pathology and bloodbrain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol 2011, 2011: 609202.PubMedGoogle Scholar
  15. [15]
    Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metalinduced neurodegeneration. J Alzheimer’s Dis 2006, 10: 223–253.Google Scholar
  16. [16]
    Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology 2000, 55: 1158–1166.PubMedCrossRefGoogle Scholar
  17. [17]
    Lye TC, Shores EA. Traumatic brain injury as a risk factor for Alzheimer’s disease: a review. Neuropsychol Rev 2000, 10: 115–129.PubMedCrossRefGoogle Scholar
  18. [18]
    Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, Takashima A, et al. Stress acts cumulatively to precipitate Alzheimer’s disease-like tau pathology and cognitive deficits. J Neurosci 2011, 31: 7840–7847.PubMedCrossRefGoogle Scholar
  19. [19]
    Tran TT, Srivareerat M, Alkadhi KA. Chronic psychosocial stress accelerates impairment of long-term memory and late-phase long-term potentiation in an at-risk model of Alzheimer’s disease. Hippocampus 2011, 21: 724–732.PubMedCrossRefGoogle Scholar
  20. [20]
    Keller JN. Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer’s disease. J Biomed Biotechnol 2006, 2006: 1–3.CrossRefGoogle Scholar
  21. [21]
    Ding QX, Dimayuga E, Keller JN. Oxidative damage, protein synthesis, and protein degradation in Alzheimer’s disease. Current Alzheimer Res 2007, 4: 73–79.CrossRefGoogle Scholar
  22. [22]
    Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, et al. A Phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol 2010, 68: 521–534.PubMedCrossRefGoogle Scholar
  23. [23]
    Bentwich J, Dobronevsky E, Aichenbaum S, Shorer R, Peretz R, Khaigrekht M, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer’s disease: a proof of concept study. J Neural Transmission 2011, 118: 463–471.CrossRefGoogle Scholar
  24. [24]
    Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs 2005, 19: 97–127.PubMedCrossRefGoogle Scholar
  25. [25]
    Ji C, Song C, Zuo P. The mechanism of memory impairment induced by Abeta chronic administration involves imbalance between cytokines and neurotrophins in the rat hippocampus. Curr Alzheimer Res 2011, 8: 410–420.PubMedCrossRefGoogle Scholar
  26. [26]
    Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010, 626: 64–71.PubMedCrossRefGoogle Scholar
  27. [27]
    Ciobica A, Padurariu M, Bild W, Stefanescu C. Cardiovascular risk factors as potential markers for mild cognitive impairment and Alzheimer’s disease. Psychiatr Danub 2011, 23: 340–346.PubMedGoogle Scholar
  28. [28]
    Trudeau F, Gagnon S, Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur J Pharmacol 2004, 490: 177–186.PubMedCrossRefGoogle Scholar
  29. [29]
    Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006, 65: 1012–1021.PubMedCrossRefGoogle Scholar
  30. [30]
    El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin: An enzyme candidate to slow the progression of Alzheimer’s disease. American J Pathology 2008, 172: 1342–1354.CrossRefGoogle Scholar
  31. [31]
    Miners JS, Kehoe P, Love S. Neprilysin protects against cerebral amyloid angiopathy and Abeta-induced degeneration of cerebrovascular smooth muscle cells. Brain Pathol 2011, 21(5):594–605.PubMedGoogle Scholar
  32. [32]
    Nicholls DG. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim Biophys Acta 2009, 1787: 1416–1424.PubMedCrossRefGoogle Scholar
  33. [33]
    Duchen MR. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med 2004, 25: 365–451.PubMedCrossRefGoogle Scholar
  34. [34]
    Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2011, 226: 2484–2493.PubMedCrossRefGoogle Scholar
  35. [35]
    Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR. Glutamate transporter variants reduce glutamate uptake in Alzheimer’s disease. Neurobiol Aging 2011, 32: 553 e551–553 e511.CrossRefGoogle Scholar
  36. [36]
    Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu YF, Wang TY, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer’s disease. Neurobiol Aging 2005, 26: 1015–1022.PubMedCrossRefGoogle Scholar
  37. [37]
    Pei JJ, Braak H, Gong CX, Grundke-Iqbal I, Iqbal K, Winblad B, et al. Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer’s disease neurofibrillary degeneration. Acta Neuropathol 2002, 104: 369–376.PubMedGoogle Scholar
  38. [38]
    Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, et al. LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56.PubMedCrossRefGoogle Scholar
  39. [39]
    Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 2004, 25: 663–674.PubMedCrossRefGoogle Scholar
  40. [40]
    Griffin R, Nally R, Nolan Y, McCartney Y, Linden J, Lynch MA. The age-related attenuation in long-term potentiation is associated with microglial activation. J Neurochem 2006, 99: 1263–1272.PubMedCrossRefGoogle Scholar
  41. [41]
    Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer’s disease. J Cell Mol Med 2008, 12: 762–780.PubMedCrossRefGoogle Scholar
  42. [42]
    Ha C, Ryu J, Park CB. Metal ions differentially influence the aggregation and deposition of Alzheimer’s beta-amyloid on a solid template. Biochemistry 2007, 46: 6118–6125.PubMedCrossRefGoogle Scholar
  43. [43]
    Zatta P, Drago D, Bolognin S, Sensi SL. Alzheimer’s disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 2009, 30: 346–355.PubMedCrossRefGoogle Scholar
  44. [44]
    Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J Neurosci 2006, 26: 10129–10140.PubMedCrossRefGoogle Scholar
  45. [45]
    Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, et al. Early onset familial Alzheimer’s disease: Mutation frequency in 31 families. Neurology 2003, 60: 235–239.PubMedCrossRefGoogle Scholar
  46. [46]
    Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer’s disease. Clin Chem Lab Med 2011, 49: 375–383.PubMedCrossRefGoogle Scholar
  47. [47]
    Hardy J, Orr H. The genetics of neurodegenerative diseases. J Neurochem 2006, 97: 1690–1699.PubMedCrossRefGoogle Scholar
  48. [48]
    Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006, 38: 24–26.PubMedCrossRefGoogle Scholar
  49. [49]
    Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain betaamyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging 2011, 38: 1702–1714.PubMedCrossRefGoogle Scholar
  50. [50]
    Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011, 10: 424–435.PubMedCrossRefGoogle Scholar
  51. [51]
    Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011, 108: 5819–5824.PubMedCrossRefGoogle Scholar
  52. [52]
    Zeng KW, Ko H, Yang HO, Wang XM. Icariin attenuates β-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology 2010, 59: 542–550.PubMedCrossRefGoogle Scholar
  53. [53]
    Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and proinflammatory signaling. J Neurosci Res 2002, 70: 462–473.PubMedCrossRefGoogle Scholar
  54. [54]
    Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer’s disease parietal cortex. J Neurochem 2002, 82: 1058–1064.PubMedCrossRefGoogle Scholar
  55. [55]
    Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brainderived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem 2005, 93: 1412–1421.PubMedCrossRefGoogle Scholar
  56. [56]
    Selkoe DJ. Alzheimer’s disease. Cold Spring Harb Perspect Biol 2011: Epub.Google Scholar
  57. [57]
    Seeman P, Seeman N. Alzheimer’s disease: beta-amyloid plaque formation in human brain. Synapse 2011, 65(12): 1289–1297.PubMedCrossRefGoogle Scholar
  58. [58]
    Ohyagi Y. Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer’s disease. Curr Alzheimer Res 2008, 5: 555–561.PubMedCrossRefGoogle Scholar
  59. [59]
    Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer’s disease. Science 2006, 314: 781–784.PubMedCrossRefGoogle Scholar
  60. [60]
    West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. Lancet 1994, 344: 769–772.PubMedCrossRefGoogle Scholar
  61. [61]
    Bobinski M, Wegiel J, Tarnawski M, Bobinski M, Reisberg B, de Leon MJ, et al. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol 1997, 56: 414–420.PubMedCrossRefGoogle Scholar
  62. [62]
    Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology 2001, 56: 127–129.PubMedCrossRefGoogle Scholar
  63. [63]
    Capsoni S, Giannotta S, Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer’s disease based on transgenic anti-nerve growth factor antibodies. Mol Cell Neurosci 2002, 21: 15–28.PubMedCrossRefGoogle Scholar
  64. [64]
    Houeland G, Romani A, Marchetti C, Amato G, Capsoni S, Cattaneo A, et al. Transgenic mice with chronic NGF deprivation and Alzheimer’s disease-like pathology display hippocampal region-specific impairments in short- and long-term plasticities. J Neurosci 2010, 30: 13089–13094.PubMedCrossRefGoogle Scholar
  65. [65]
    Matrone C, Di Luzio A, Meli G, D’Aguanno S, Severini C, Ciotti MT, et al. Activation of the amyloidogenic route by NGF deprivation induces apoptotic death in PC12 cells. J Alzheimers Dis 2008, 13: 81–96.PubMedGoogle Scholar
  66. [66]
    Matrone C, Ciotti MT, Mercanti D, Marolda R, Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc Natl Acad Sci U S A 2008, 105: 13139–13144.PubMedCrossRefGoogle Scholar
  67. [67]
    Wang YJ, Wang X, Lu JJ, Li QX, Gao CY, Liu XH, et al. p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. J Neurosci 2011, 31: 2292–2304.PubMedCrossRefGoogle Scholar
  68. [68]
    Zeng F, Lu JJ, Zhou XF, Wang YJ. Roles of p75NTR in the pathogenesis of Alzheimer’s disease: a novel therapeutic target. Biochem Pharmacol 2011, 82: 1500–1509.PubMedCrossRefGoogle Scholar
  69. [69]
    Capsoni S, Tiveron C, Vignone D, Amato G, Cattaneo A. Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration. Proc Natl Acad Sci U S A 2010, 107: 12299–12304.PubMedCrossRefGoogle Scholar
  70. [70]
    Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9: 363–372.PubMedCrossRefGoogle Scholar
  71. [71]
    Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73: 2061–2070.PubMedCrossRefGoogle Scholar
  72. [72]
    Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of A beta(42) immunisation in Alzheimer’s disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 2008, 372: 216–223.PubMedCrossRefGoogle Scholar
  73. [73]
    Imbimbo BP, Giardina GA. Gamma-secretase inhibitors and modulators for the treatment of Alzheimer’s disease: disappointments and hopes. Curr Top Med Chem 2011, 11: 1555–1570.PubMedCrossRefGoogle Scholar
  74. [74]
    Vellas B. Tarenflurbil for Alzheimer’s disease: a “shot on goal” that missed. Lancet Neurol 2010, 9: 235–237.PubMedCrossRefGoogle Scholar
  75. [75]
    Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D’Onofrio G, Logroscino G, et al. Therapeutic intervention for Alzheimer’s disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011, 20: 325–341.PubMedCrossRefGoogle Scholar
  76. [76]
    Sabbagh MN. Drug development for Alzheimer’s disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009, 7: 167–185.PubMedCrossRefGoogle Scholar
  77. [77]
    D’Alton S, George DR. Changing perspectives on Alzheimer’s disease: thinking outside the amyloid box. J Alzheimers Dis 2011: Epub ahead of print.Google Scholar
  78. [78]
    Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer’s disease, an early interim report. Exp Neurol 2010, 223: 252–266.PubMedCrossRefGoogle Scholar
  79. [79]
    Selkoe DJ. Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med 2011, 17: 1060–1065.PubMedCrossRefGoogle Scholar
  80. [80]
    Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002, 3: 688–694.PubMedCrossRefGoogle Scholar
  81. [81]
    Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron 2011, 69: 203–213.PubMedCrossRefGoogle Scholar
  82. [82]
    Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010, 6: 108–119.PubMedCrossRefGoogle Scholar
  83. [83]
    Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27: 3650–3662.PubMedCrossRefGoogle Scholar
  84. [84]
    Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, et al. Defective brain microtubule assembly in Alzheimer’s disease. Lancet 1986, 2: 421–426.PubMedCrossRefGoogle Scholar
  85. [85]
    Liu R, Pei JJ, Wang XC, Zhou XW, Tian Q, Winblad B, et al. Acute anoxia induces tau dephosphorylation in rat brain slices and its possible underlying mechanisms. J Neurochem 2005, 94: 1225–1234.PubMedCrossRefGoogle Scholar
  86. [86]
    Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, et al. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 2003, 87: 1333–1344.PubMedCrossRefGoogle Scholar
  87. [87]
    Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011, 198: 351–356.PubMedCrossRefGoogle Scholar
  88. [88]
    Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7: 402–411.PubMedCrossRefGoogle Scholar
  89. [89]
    Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 2000, 1502: 139–144.PubMedCrossRefGoogle Scholar
  90. [90]
    Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol 2002, 2: 120–123.PubMedCrossRefGoogle Scholar
  91. [91]
    Rutten BP, Steinbusch HW, Korr H, Schmitz C. Antioxidants and Alzheimer’s disease: from bench to bedside (and back again). Curr Opin Clin Nutr Metab Care 2002, 5: 645–651.PubMedCrossRefGoogle Scholar
  92. [92]
    Hammarlund M, Nix P, Hauth L, Jorgensen EM, Bastiani M. Axon regeneration requires a conserved MAP kinase pathway. Science 2009, 323: 802–806.PubMedCrossRefGoogle Scholar
  93. [93]
    Case LC, Tessier-Lavigne M. Regeneration of the adult central nervous system. Curr Biol 2005, 15: R749–753.PubMedCrossRefGoogle Scholar
  94. [94]
    Yuen EC, Howe CL, Li Y, Holtzman DM, Mobley WC. Nerve growth factor and the neurotrophic factor hypothesis. Brain Dev 1996, 18: 362–368.PubMedCrossRefGoogle Scholar
  95. [95]
    Hu B, Nikolakopoulou AM, Cohen-Cory S. BDNF stabilizes synapses and maintains the structural complexity of optic axons in vivo. Development 2005, 132: 4285–4298.PubMedCrossRefGoogle Scholar
  96. [96]
    Grimes ML, Zhou J, Beattie EC, Yuen EC, Hall DE, Valletta JS, et al. Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. J Neurosci 1996, 16: 7950–7964.PubMedGoogle Scholar
  97. [97]
    Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brainderived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 2009, 15: 331–337.PubMedCrossRefGoogle Scholar
  98. [98]
    Fjord-Larsen L, Kusk P, Emerich DF, Thanos C, Torp M, Bintz B, et al. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. Gene Ther 2011, 19(10): 1010–1017PubMedCrossRefGoogle Scholar
  99. [99]
    Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001, 24: 677–736.PubMedCrossRefGoogle Scholar
  100. [100]
    Lin LF, Xue XY, Liao MJ, Xiao F, Lv RH, Luo HM. Neurotrophic effects of magnesium fructose 1,6-diphosphate on cortical neurons. Int J Neurosci 2011, 122: 248–254.CrossRefGoogle Scholar
  101. [101]
    Matsui N, Takahashi K, Takeichi M, Kuroshita T, Noguchi K, Yamazaki K, et al. Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice. Brain Res 2009, 1305: 108–117.PubMedCrossRefGoogle Scholar
  102. [102]
    Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol 2011, 18: 59–68.PubMedCrossRefGoogle Scholar
  103. [103]
    Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl 2002: 277–285.Google Scholar
  104. [104]
    Rossler M, Zarski R, Bohl J, Ohm TG. Stage-dependent and sector-specific neuronal loss in hippocampus during Alzheimer’s disease. Acta Neuropathol 2002, 103: 363–369.PubMedCrossRefGoogle Scholar
  105. [105]
    Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68: 1501–1508.PubMedCrossRefGoogle Scholar
  106. [106]
    Reiman EM, Langbaum JB, Tariot PN. Alzheimer’s prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010, 4: 3–14.PubMedCrossRefGoogle Scholar
  107. [107]
    Chopra K, Misra S, Kuhad A. Current perspectives on pharmacotherapy of Alzheimer’s disease. Expert Opin Pharmacother 2011, 12: 335–350.PubMedCrossRefGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Lian-Feng Lin
    • 1
  • Min-Jing Liao
    • 1
    • 4
  • Xiao-Yan Xue
    • 5
  • Wei Zhang
    • 1
  • Li Yan
    • 1
  • Liang Cai
    • 1
  • Xiao-Wen Zhou
    • 1
  • Xing Zhou
    • 1
  • Huan-Min Luo
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of PharmacologyJinan UniversityGuangzhouChina
  2. 2.Institute of Brain Sciences, School of MedicineJinan UniversityGuangzhouChina
  3. 3.The Joint Laboratory of Brain Function and HealthJinan University and The University of Hong Kong, Jinan UniversityGuangzhouChina
  4. 4.Department of Laboratory MedicineMedical College of Hunan Normal UniversityChangshaChina
  5. 5.Ganzhou People’s HospitalGanzhouChina

Personalised recommendations